Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
